Immunocore’s investigational immunotherapy tebentafusp (IMCgp100) is superior to investigator’s choice at prolonging the lives of adults newly diagnosed with metastatic uveal melanoma — a common and hard-to-treat form of eye cancer, interim data from a Phase 3 trial show. These preliminary findings add to the positive survival benefits reported with tebentafusp’s use in a Phase 2 trial of people previously treated for this cancer, supporting the therapy’s potential in this patient population. “A positive survival…
You must be logged in to read/download the full post.
The post Tebentafusp Prolongs Life for Those With Advanced Eye Cancer, Trial Finds appeared first on BioNewsFeeds.